218 related articles for article (PubMed ID: 17651539)
41. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
Arboleya LR; de la Figuera E; Soledad García M; Aragón B;
Curr Med Res Opin; 2003; 19(4):288-97. PubMed ID: 12841921
[TBL] [Abstract][Full Text] [Related]
42. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
43. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
[TBL] [Abstract][Full Text] [Related]
45. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial.
Adams KF; Chen C; Newton KM; Potter JD; Lampe JW
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):644-8. PubMed ID: 15066931
[TBL] [Abstract][Full Text] [Related]
46. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Fredy J; Diggins DA; Morrill GB
Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
[TBL] [Abstract][Full Text] [Related]
47. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis.
Cobellis L; Razzi S; De Simone S; Sartini A; Fava A; Danero S; Gioffrè W; Mazzini M; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2004 Sep; 116(1):100-2. PubMed ID: 15294376
[TBL] [Abstract][Full Text] [Related]
48. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
Schug SA; Joshi GP; Camu F; Pan S; Cheung R
Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866
[TBL] [Abstract][Full Text] [Related]
49. The patient's perspective on the recall of Vioxx.
Hawker GA; Katz JN; Solomon DH
J Rheumatol; 2006 Jun; 33(6):1082-8. PubMed ID: 16755654
[TBL] [Abstract][Full Text] [Related]
50. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
51. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
52. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
[TBL] [Abstract][Full Text] [Related]
53. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
Leung WK; Ng EK; Chan FK; Chan WY; Chan KF; Auyeung AC; Lam CC; Lau JY; Sung JJ
Clin Cancer Res; 2006 Aug; 12(15):4766-72. PubMed ID: 16899628
[TBL] [Abstract][Full Text] [Related]
54. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine.
Silberstein S; Tepper S; Brandes J; Diamond M; Goldstein J; Winner P; Venkatraman S; Vrijens F; Malbecq W; Lines C; Visser WH; Reines S; Yuen E
Neurology; 2004 May; 62(9):1552-7. PubMed ID: 15136680
[TBL] [Abstract][Full Text] [Related]
55. The safety of rofecoxib.
Burnier M
Expert Opin Drug Saf; 2005 May; 4(3):491-9. PubMed ID: 15934855
[TBL] [Abstract][Full Text] [Related]
56. Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx).
Meyer CH; Schmidt JC; Rodrigues EB; Mennel S
Ophthalmologica; 2005; 219(4):243-7. PubMed ID: 16088245
[TBL] [Abstract][Full Text] [Related]
57. Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial.
Beauchant M; Ingrand P; Favriel JM; Dupuychaffray JP; Capony P; Moindrot H; Barthet M; Escourrou J; Plane C; Barrioz T; Lacoste L; Ingrand I
Endoscopy; 2008 Aug; 40(8):631-6. PubMed ID: 18680075
[TBL] [Abstract][Full Text] [Related]
58. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
59. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
60. Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Lekakis JP; Vamvakou G; Andreadou I; Ganiatsos G; Karatzis E; Protogerou A; Papaioannou T; Ikonomidis I; Papamichael C; Mavrikakis ME
Int J Cardiol; 2006 Oct; 112(3):359-66. PubMed ID: 16330117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
